Northwest Biotherapeutics, Inc. (NWBO)
0.1537
0.00 (0.00%)
USD |
OTCM |
Oct 02, 16:00
Northwest Biotherapeutics Net Income (Quarterly) : -9.221M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.221M |
| March 31, 2026 | -3.069M |
| December 31, 2025 | 1.388M |
| September 30, 2025 | -26.83M |
| June 30, 2025 | -15.38M |
| March 31, 2025 | -19.34M |
| December 31, 2024 | -28.22M |
| September 30, 2024 | -19.37M |
| June 30, 2024 | -17.87M |
| March 31, 2024 | -18.31M |
| December 31, 2023 | -18.92M |
| September 30, 2023 | -18.58M |
| June 30, 2023 | -14.45M |
| March 31, 2023 | -10.65M |
| December 31, 2022 | -28.30M |
| September 30, 2022 | -32.85M |
| June 30, 2022 | -29.67M |
| March 31, 2022 | -14.21M |
| December 31, 2021 | 133.32M |
| September 30, 2021 | 45.52M |
| June 30, 2021 | 4.41M |
| March 31, 2021 | -4.123M |
| December 31, 2020 | -280.30M |
| September 30, 2020 | -194.10M |
| June 30, 2020 | -58.05M |
| Date | Value |
|---|---|
| March 31, 2020 | 2.626M |
| December 31, 2019 | 6.545M |
| September 30, 2019 | -6.371M |
| June 30, 2019 | 0.219M |
| March 31, 2019 | -20.95M |
| September 30, 2018 | 12.58M |
| June 30, 2018 | -21.18M |
| March 31, 2018 | -21.54M |
| December 31, 2017 | -27.00M |
| September 30, 2017 | -23.27M |
| June 30, 2017 | -10.25M |
| March 31, 2017 | -12.62M |
| December 31, 2016 | -30.71M |
| September 30, 2016 | -32.23M |
| June 30, 2016 | -16.82M |
| March 31, 2016 | -6.106M |
| December 31, 2015 | -24.08M |
| September 30, 2015 | 22.62M |
| June 30, 2015 | -66.84M |
| March 31, 2015 | -46.43M |
| December 31, 2014 | -42.68M |
| September 30, 2014 | -21.04M |
| June 30, 2014 | -25.86M |
| March 31, 2014 | -46.04M |
| December 31, 2013 | -16.89M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 31.50M |
| Alnylam Pharmaceuticals, Inc. | 164.49M |
| Savara, Inc. | -40.23M |
| Vericel Corp. | 2.206M |
| Biogen, Inc. | 97.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.807M |
| Total Expenses (Quarterly) | 10.03M |
| EPS Diluted (Quarterly) | -0.0058 |
| Enterprise Value | 329.47M |
| Gross Profit Margin (Quarterly) | -5.58% |
| Profit Margin (Quarterly) | -1.14K% |
| Earnings Yield | -16.53% |
| Normalized Earnings Yield | -23.16 |